Development and Clinical Application of a Highly Sensitive Enzyme Immunoassay (EIA) for Human Growth Hormone- Releasing Hormone (hGHRH) in Plasma

Katakami, Hideki; Hashida, Seiichi; Hidaka, Hiroyuki; Ishikawa, Eiji; Matsukura, Shigeru

doi:10.1507/endocrj.45.suppl_s67

Cited by 10 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 We also reported that 60.0% of the somatotroph adenoma was immunopositive for GHRH, revealed by a highly sensitive catalyzed signal amplification system. 10 Other recent reports show the presence of GHRH synthesis in the pituitary somatotroph adenoma. 10 Other recent reports show the presence of GHRH synthesis in the pituitary somatotroph adenoma.…”

Section: Discussionmentioning

confidence: 94%

Effective Combined Medical Treatment With Octreotide Long Acting Release (Sandostatin LAR) and Cabergoline for an Extremely Rare Pituitary Somatotroph Adenoma Producing Growth Hormone-Releasing Hormone

Matsuno¹,

Katakami²,

Okazaki³

et al. 2008

The Endocrinologist

Self Cite

View full text Add to dashboard Cite

Combined medical treatment with long acting octreotide and cabergoline is now used with active patients with acromegaly and can reduce serum growth hormone (GH) and insulin-like growth factor-1 levels. In this article, we analyzed again the molecular aspects of the previously reported rare GH-releasing hormone (GHRH)-producing somatotroph adenoma, and introduce the effects of the combined medical treatment using octreotide LAR and cabergoline for GHRH-producing somatotroph adenoma. The present GHRH-producing somatotroph adenoma had a high Ki-67 staining index, weak, and cytoplasmic-dominant immunostaining of somatostatin receptor 2A, and no gsp mutation. This adenoma was predicted to be resistant to the medical therapy using octreotide LAR. In this extremely rare GHRH-producing pituitary somatotroph adenoma, octreotide LAR alone cannot reduce random GH and insulin-like growth factor-1 levels sufficiently, but combined medical therapy with octreotide LAR and cabergoline can reduce them into the normal range. We show that combined medical treatment with octreotide LAR and cabergoline was effective for a somatotroph adenoma that had a high proliferative potential, weak and cytoplasmic-dominant immunostaining of somatostatin receptor 2A, and no gsp mutation, and has active GH production and secretion regulated by locally generated GHRH from adenoma cell.

show abstract

Section: Discussionmentioning

confidence: 94%

Effective Combined Medical Treatment With Octreotide Long Acting Release (Sandostatin LAR) and Cabergoline for an Extremely Rare Pituitary Somatotroph Adenoma Producing Growth Hormone-Releasing Hormone

Matsuno¹,

Katakami²,

Okazaki³

et al. 2008

The Endocrinologist

Self Cite

View full text Add to dashboard Cite

show abstract

“…The serum GH levels were modestly elevated (Tables 1 , 2 2 ) despite hyperglycemia, and paradoxically responded to an intravenous thyrotropin-releasing hormone (TRH) challenge ( Table 2 ). The plasma levels of GHRH were as high as 9,230.4 pg/mL (reference range, 4 ~14) ( 4 ) ( Table 1 ).…”

Section: Case Reportmentioning

confidence: 99%

Metastatic Pancreatic Neuroendocrine Tumor that Progressed to Ectopic Adrenocorticotropic Hormone (ACTH) Syndrome with Growth Hormone-releasing Hormone (GHRH) Production

et al. 2016

Self Cite

View full text Add to dashboard Cite

The patient was a 61-year-old woman who had a well-differentiated pancreatic neuroendocrine tumor (PNET) with lymph node metastasis. After 15 months of octreotide treatment, glucose control deteriorated and pigmentation of the tongue and moon face developed, leading to the diagnosis of ectopic adrenocorticotropic hormone (ACTH) syndrome. An abnormal secretion of growth hormone (GH) was identified, and the plasma growth hormone-releasing hormone (GHRH) level was elevated. A tumor biopsy specimen positively immunostained for ACTH and GHRH. Ectopic hormone secretion seems to have evolved along with the progression of the PNET.

show abstract

“…To exclude the hyperplastic expansion of the remnant pituitary tissues in the sphenoid sinus due to circulating GHRH produced by neoplasms, we measured plasma GHRH concentration, which was determined to be 3.9 pg/mL (normal range: 4–12 pg/mL). The measurement of plasma GHRH concentration was detailed in the previous reports 24–26 …”

Section: Case Reportmentioning

confidence: 99%

Ectopic pituitary adenoma in the sphenoid sinus causing acromegaly associated with empty sella

Matsuno

Katayama

Okazaki

et al. 2001

ANZ Journal of Surgery

View full text Add to dashboard Cite

Development and Clinical Application of a Highly Sensitive Enzyme Immunoassay (EIA) for Human Growth Hormone- Releasing Hormone (hGHRH) in Plasma

Cited by 10 publications

References 16 publications

Effective Combined Medical Treatment With Octreotide Long Acting Release (Sandostatin LAR) and Cabergoline for an Extremely Rare Pituitary Somatotroph Adenoma Producing Growth Hormone-Releasing Hormone

Effective Combined Medical Treatment With Octreotide Long Acting Release (Sandostatin LAR) and Cabergoline for an Extremely Rare Pituitary Somatotroph Adenoma Producing Growth Hormone-Releasing Hormone

Metastatic Pancreatic Neuroendocrine Tumor that Progressed to Ectopic Adrenocorticotropic Hormone (ACTH) Syndrome with Growth Hormone-releasing Hormone (GHRH) Production

Ectopic pituitary adenoma in the sphenoid sinus causing acromegaly associated with empty sella

Contact Info

Product

Resources

About